Another multi-institutional clinical trial also reported cases of retained AR expression and activity in prostate cancer with neuroendocrine differentiation, supporting the clinical value of further investigation in these AR/NE double-positive prostate cancer (6). This evidence concerns the gene AR and prostate carcinoma.